Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

Journal:

Nature Communications

Published:

2026-03-26

DOI:

10.1038/s41467-026-71102-x

Affiliations:

4

Authors:

21

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	18.000000 18.000000	0.86
Brigham and Women's Hospital (BWH), United States of America (USA)	1.000000	0.05
UMass Memorial Health, United States of America (USA)	1.000000	0.05
Northwell Health, United States of America (USA)	1.000000	0.05

Interested in Oncology and Carcinogenesis?